Jan 13, 2025
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Jan 13, 2025
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 09, 2025
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 07, 2025
CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
Jan 03, 2025
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Dec 13, 2024
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Dec 11, 2024
AbbVie Completes Acquisition of Aliada Therapeutics
Dec 09, 2024
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Dec 09, 2024
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec 08, 2024
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
Dec 07, 2024
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Nov 25, 2024
AbbVie to Present at Citi's 2024 Global Healthcare Conference
Nov 18, 2024
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
Nov 18, 2024
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Nov 14, 2024
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
Nov 11, 2024
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
Nov 07, 2024
Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
Oct 31, 2024
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Oct 30, 2024
AbbVie Reports Third-Quarter 2024 Financial Results
Oct 28, 2024
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline